Kings Point Capital Management’s Genmab GMAB Stock Holding History

Kings Point Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$23K	Hold	625	–	–	﹤0.01%	457
2021 Q4	$25K	Hold	625	–	–	﹤0.01%	491
2021 Q3	$27K	Hold	625	–	–	﹤0.01%	443
2021 Q2	$26K	Hold	625	–	–	﹤0.01%	428
2021 Q1	$21K	Buy	+625	New	+$23.5K	﹤0.01%	451

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kings Point Capital Management's GMAB Position: Q1 2022 in Review

Kings Point Capital Management held its Genmab (GMAB) position steady in Q1 2022 at 625 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

Kings Point Capital Management first reported a position in GMAB in Q1 2021 and has held it in 5 quarters since. The position peaked at $27K in Q3 2021. 204 funds tracked by Wall St. Rank hold GMAB as of Q1 2022.

Kings Point Capital Management held 625 shares of Genmab worth $23K as of Q1 2022.
Kings Point Capital Management left its Genmab share count unchanged in Q1 2022.
Genmab made up ﹤0.01% of Kings Point Capital Management's portfolio in Q1 2022, its #457 holding.
Kings Point Capital Management first reported a position in Genmab in Q1 2021 and has held it in 5 quarters since.
Kings Point Capital Management's Genmab position peaked at $27K in Q3 2021.
204 funds tracked by Wall St. Rank held Genmab as of Q1 2022.

Based on Kings Point Capital Management's 13F filing for Q1 2022, filed 13 May 2022.